Association of antidiabetic medications with psychiatric disorders in patients with type 2 diabetes: a cross-sectional study
Abstract
Antihyperglycemic medications can affect more than just glucose control; they may also influence mental health outcomes. This study aimed to investigate the relationships between various antidiabetic medications and psychiatric disorders, including depression, anxiety, and sleep disturbances, in individuals with type 2 diabetes (T2DM). This cross-sectional study analyzed data from patients with T2DM, assessing psychiatric outcomes among these patients using various antidiabetic therapies. Sleep quality, anxiety, and depression were measured using validated scales, including the Pittsburgh Sleep Quality Index (PSQI), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9), respectively. This study involved 229 patients with a mean age ± standard deviation of 63.43 ± 10.38 years. The median body mass index (BMI) was 27.18 kg/m2, with an interquartile range (IQR) of 24.55–30.10, and the median duration of diabetes was 11.00 years (IQR: 6.00–16.00). The use of sodium glucose cotransporter-2 (SGLT-2) inhibitors was significantly associated with poorer sleep quality, as indicated by a higher odds ratio (odds ratio [OR] = 2.076, 95% confidence interval [CI]: 1.016–4.242, P = 0.045). Insulin use was linked to increased anxiety, with an OR of 1.985 (95% CI: 1.007–3.913, P = 0.048). In contrast, sulfonylureas and glinides were associated with lower odds of depression, with an OR of 0.374 (95% CI: 0.182–0.768, P = 0.007). No significant associations were…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 229 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.